Plasma proteome analysis for anti-obesity and anti-diabetic potentials of chitosan oligosaccharides in ob/ob mice

Proteomics

Volumn 9, Issue 8, 2009, Pages 2149-2162

  Kumar, Suresh G ^a   Md Rahman, Atiar ^a   Lee, Sung Hak ^a   Hwang, Hee Sun ^a   Kim, Hyun Ah ^a   Yun, Jong Won ^a  

^a Daegu University   (South Korea)

Author keywords

Adipokines; Chitosan oligosaccharides; Diabetes; Obesity; Plasma proteome

Indexed keywords

ADIPOCYTOKINE; INTERLEUKIN 6; PROTEOME; TUMOR NECROSIS FACTOR ALPHA;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CONTROLLED STUDY; DIABETES MELLITUS; DOWN REGULATION; GENE EXPRESSION; GLUCOSE TOLERANCE TEST; HYPERLIPIDEMIA; MALE; MOUSE; NONHUMAN; OBESITY; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN BLOOD LEVEL; PROTEIN SYNTHESIS; PROTEOMICS;

ADIPOKINES; ANIMALS; ANTICHOLESTEREMIC AGENTS; APOLIPOPROTEINS; BLOOD GLUCOSE; BODY WEIGHT; CHITOSAN; CHOLESTEROL; DIABETES MELLITUS; EATING; GENE EXPRESSION REGULATION; GLUTATHIONE PEROXIDASE; INJECTIONS, INTRAPERITONEAL; MICE; OBESITY; PROTEOME; RETINOL-BINDING PROTEINS, PLASMA; TRIGLYCERIDES;

MUS;

EID: 65349101598     PISSN: 16159853     EISSN: 16159861     Source Type: Journal    
DOI: 10.1002/pmic.200800571     Document Type: Article

References (88)

1. Aguilera, C. M., Gil, C. M., Canete, R., Gil, A., Alterations in plasma and tissue lipids associated with obesity and metabolic syndrome. Clin. Sci. 2008, 114, 183-193.
2. Hotamisligil, G. S., Molecular mechanisms of insulin resistance and the role of the adipocyte. Int. J. Obes. Relat. Metab. Disord. 2000, 24, 23-27.
3. Bastard, J. P., Maachi, M., Lagathu, C., Kim, M. J., Caron, M., Vidal, H., Capeau, J., Feve, B., Recent advances in the relationship between obesity, inflammation, and insulin resistance. Eur. Cytokine Netw. 2006, 17, 4-12.
4. Palomo, I., Alarcon, M., Moore, C. R., Argiles, J. M., Hemostasis alterations in metabolic syndrome. Int. J. Mol. Med. 2006, 18, 969-974.
5. Badman, M. K., Flier, J. S., The adipocyte as an active participant in energy balance and metabolism. Gastroenterology 2007, 132, 2103-2115.
6. Wassink, A. M., Olijhoek, J. K., Visseren, F. L., The metabolic syndrome: metabolic changes with vascular consequences. Eur. J. Clin. Invest. 2007, 37, 8-17.
7. DeFronzo, R. A., Pharmacologic therapy for T2DM. Ann. Intern. Med. 1999, 131, 281-303.
8. Ajjan, R. A., Grant, P. J., Cardiovascular disease prevention in patients with type 2 diabetes: the role of oral anti-diabetic agents. Diab. Vasc. Dis. Res. 2006, 3, 147-158.
9. Miura, T., Usami, M., Tsuura, Y., Ishida, H., Seino, Y., Hypoglycemic and hypolipidemic effect of chitosan in normal and neonatal streptozotocin-induced diabetic mice. Biol. Pharm. Bull. 1995, 18, 1623-1625.
10. Mhurchu, C. N., Poppitt, S. D., McGill, A. T., Leahy, F. E. et al., The effect of the dietary supplement, Chitosan, on body weight: a randomised controlled trial in 250 overweight and obese adults. Int. J. Obes. Relat. Metab. Disord. 2004, 28, 1149-1156.
11. Cherniak, E. P., Potential applications for alternative medicine to treat obesity in an aging population. Altern. Med. Rev. 2008, 13, 34-42.
12. Sumiyoshi, M., Kimura, Y., Low molecular weight chitosan inhibits obesity induced by feeding a high-fat diet long-term in mice. J. Pharm. Pharmacol. 2006, 58, 201-207.
13. Hayashi, K., Ito, M., Antidiabetic action of low molecular weight chitosan in genetically obese diabetic KK-Ay mice. Biol. Pharm. Bull. 2002, 25, 188-192.
14. Zhang, Y., Proenca, R., Maffei, M., Barone, M. et al., Positional cloning of the mice obese gene and its human homologue. Nature 1994, 372, 425-432.
15. Sone, M., Osamura, R. Y., Leptin and the pituitary. Pituitary 2001, 4, 15-23.
16. Van den Hoek, A. M., Teusink, B., Voshol, P. J., Havekes, L. M. et al., Leptin deficiency per se dictates body composition and insulin action in ob/ob mice. J. Neuroendocrinol. 2008, 20, 120-127.
17. Seely, B. L., Olefsky, J. M., Potential cellular and genetic mechanisms for insulin resistance in common disorders of obesity and diabetes. In: Insulin Resistance and Its Clinical Disorders. Moller D., Ed. Chichester, U. K., Wiley, 1993, pp. 187-252.
18. Zolg, J. W., Langen, H., How industry is approaching the search for new diagnostic markers and biomarkers. Mol. Cell. Proteomics 2004, 3, 345-354.
19. Noh, K. S., Lee, D. Y., Cha, J. H., Joo, W. A. et al., Protein biomarkers in the plasma of workers occupationally exposed to polycyclic aromatic hydrocarbons. Proteomics 2004, 4, 3505-3513.
20. Cristea, I. M., Gaskell, S. J., Whetton, A. D., Proteomics techniques and their application to hematology. Blood 2004, 103, 3624-3634.
21. Baussant, T., Bougueleret, L., Johnson, A., Rogers, J. et al., Effective depletion of albumin using a new peptide-based affinity medium. Proteomics 2005, 5, 973-977.
22. Kim, S. W., Hwang, H. J., Kim, H. M., Lee, M. C. et al., Effect of fungal polysaccharides on the modulation of plasma proteins in streptozotocin-induced diabetic rats. Proteomics 2006, 6, 5291-5302.
23. Kim, S. W., Hwang, H. J., Cho, E. J., Oh, J. Y. et al., Time-dependent plasma protein changes in streptozotocin-induced diabetic rats before and after fungal polysaccharide treatments. J. Proteome Res. 2006, 5, 2966-2976.
24. Renes, J., Bouwman, F., Noben, J. P., Evelo, C. et al., Protein profiling of 3T3-L1 adipocyte differentiation and (tumor necrosis factor alpha-mediated) starvation. Cell. Mol. Life. Sci. 2005, 62, 492-503.
25. Schmid, G. M., Converset, V., Walter, N., Sennitt, M. V. et al., Effect of high-fat diet on the expression of proteins in muscle, adipose tissues, and liver of C57BL/6 mice. Proteomics 2004, 4, 2270-2282.
26. Cho, E. J., Rahman, M. A., Kim, S. W., Baek, Y. M. et al., Chitosan oligosaccharides inhibit adipogenesis in 3T3-L1 adipocytes. J. Microbiol. Biotechnol. 2008, 18, 80-87.
27. Rahman, A., Kumar, S. G., Kim, S. W., Hwang, H. J. et al., Proteomic analysis for inhibitory effect of chitosan oligosaccharides on 3T3-L1 adipocyte differentiation. Proteomics 2008, 8, 569-581.
28. Bradford, M. M., A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. Anal. Biochem. 1976, 72, 248-254.
29. Shevchenko, A., Wilm, M., Vorm, O., Mann, M., Mass spectrometric sequencing of proteins from silver stained gels. Anal. Chem. 1996, 68, 850-858.
30. Kondo, Y., Nakatani, A., Hayashi, K., Ito, M., Low molecular weight chitosan prevents the progression of low dose streptozotocin-induced slowly progressive diabetes mellitus in mice. Biol. Pharm. Bull. 2000, 23, 1458-1464.
31. Lee, H. W., Park, Y. S., Choi, J. W., Yi, S. Y., Shin, W. S., Antidiabetic effects of chitosan oligosaccharides in neonatal streptozotocin-induced noninsulin-dependent diabetes mellitus in rats. Biol. Pharm. Bull. 2003, 26, 1100-1103.
32. Wuolijoki, E., Hirvela, T., Ylitalo, P., Decrease in serum LDL cholesterol with microcrystalline chitosan. Methods Find Exp. Clin. Pharmacol. 1999, 21, 357-361.
33. Weisberg, S. P., Leibel, R., Tortoriello, D. V., Dietary curcumin significantly improves obesity-associated inflammation and diabetes in mice models of diabesity. Endocrinology 2008 Apr 10; [Epub ahead of print]
34. Gault, V. A., McClean, P. L., Cassidy, R. S., Irwin, N., Flatt, P. R., Chemical gastric inhibitory polypeptide receptor antagonism protects against obesity, insulin resistance, glucose intolerance and associated disturbances in mice fed high-fat and cafeteria diets. Diabetologia 2007, 50, 1752-1762.
35. Flachs, P., Mohamed-Ali, V., Horakova, O., Rossmeisl, M. et al., Polyunsaturated fatty acids of marine origin induce adiponectin in mice fed a high-fat diet. Diabetologia 2006, 49, 394-397.
36. Rau, O., Zettl, H., Popescu, L., Steinhilber, D., Schubert-Zsilavecz, M., The treatment of dyslipidemia-what's left in the pipeline? ChemMedChem. 2008, 3, 206-221.
37. Greenow, K., Pearce, N. J., Ramji, D. P., The key role of apolipoprotein E in atherosclerosis. J. Mol. Med. 2005, 83, 329-342.
38. Stan, S., Delvin, E., Lambert, M., Seidman, E., Levy, E., ApoA-IV: an update on regulation and physiologic functions. Biochim. Biophys. Acta. 2003, 1631, 177-187.
39. Fujimoto, K., Fukagawa, K., Sakata, T., Tso, P., Suppression of food intake by apolipoprotein A-IV is mediated through the central nervous system in rats. J. Clin. Invest. 1993, 91, 1830-1833.
40. Gavi, S., Stuart, L. M., Kelly, P., Melendez, M. M. et al., Retinol-binding protein 4 is associated with insulin resistance and body fat distribution in non obese subjects without type 2 diabetes. J. Clin. Endocrinol. Metab. 2007, 92, 1886-1890.
41. Graham, T. E., Yang, Q., Bluher, M., Hammarstedt, A. et al., Retinol-binding protein 4 and insulin resistance in lean, obese, and diabetic subjects. N. Engl. J. Med. 2006, 354, 2552-2563.
42. Mody, N., Graham, T. E., Tsuji, Y., Yang, Q., Kahn, B. B., Decreased clearance of serum retinol-binding protein and elevated levels of transthyretin in insulin-resistant ob/ob mice. Am. J. Physiol. Endocrinol. Metab. 2008, 294,785-793.
43. Kloting, N., Graham, T. E., Berndt, J., Kralisch, S. et al., Serum retinol-binding protein is more highly expressed in visceral than in subcutaneous adipose tissue and is a marker of intra-abdominal fat mass. Cell. Metab. 2007, 6, 79-87
44. Yang, Q., Graham, T. E., Mody, N., Preitner, F. et al., Serum retinol binding protein 4 contributes to insulin resistance in obesity and type 2 diabetes. Nature 2005, 436, 356-362.
45. Kawashiri, M. A., Maugeais, C., Rader, D. J., High-density lipoprotein metabolism: molecular targets for new therapies for atherosclerosis. Curr. Atheroscler. Rep. 2000, 2, 363-372.
46. O'Brien, T., Nguyen, T. T., Hallaway, B. J., Hodge, D. et al., The role of lipoprotein A-I and lipoprotein A-I/A-II in predicting coronary artery disease. Arterioscler. Thromb. Vasc. Biol. 1995, 15, 228-231.
47. Watson, A. M., Poloyac, S. M., Howard, G., Blouin, R. A., Effect of leptin on cytochrome P-450, conjugation, and antioxidant enzymes in the ob/ob mouse. Drug. Metab. Dispos. 1999, 27, 695-700.
48. Ozata, M., Uckaya, G., Aydin, A., Isimer, A., Ozdemir, I. C., Defective antioxidant defense system in patients with a human leptin gene mutation. Horm. Metab. Res. 2000, 32, 269-272.
49. Manjunatha, H., Srinivasan, K., Hypolipidemic and antioxidant effects of dietary curcumin and capsaicin in induced hypercholesterolemic rats. Lipids 2007, 42, 1133-1142.
50. Verges, B., Petit, J. M., Duvillard, L., Dautin, G. et al., Adiponectin is an important determinant of apoA-I catabolism. Arterioscler. Thromb. Vasc. Biol. 2006, 26, 1364-1369.
51. Yamauchi, T., Kamon, J., Waki, H., Imai, Y. et al., Globular adiponectin protected ob/ob mice from diabetes and ApoE-deficient mice from atherosclerosis. J. Biol. Chem. 2003, 278, 2461-2468.
52. Arita, Y., Kihara, S., Ouchi, N., Takahashi, M. et al., Paradoxical decrease of an adipose-specific protein, adiponectin, in obesity. Biochem. Biophys. Res. Commun. 1999, 257, 79-83.
53. Cnop, M., Havel, P. J., Utzschneider, K. M., Carr, D. B. et al., Relationship of adiponectin to body fat distribution, insulin sensitivity and plasma lipoproteins: evidence for independent roles of age and sex. Diabetologia 2003, 46, 459-469.
54. Lindsay, R. S., Funahashi, T., Hanson, R. L., Matsuzawa, Y. et al., Adiponectin and development of type 2 diabetes in the Pima Indian population. Lancet 2002, 360, 57-58.
55. Kumada, M., Kihara, S., Sumitsuji, S., Kawamoto, T. et al., Coronary artery disease. Association of hypoadiponectinemia with coronary artery disease in men. Arterioscler. Thromb. Vasc. Biol. 2003, 23, 85-89.
56. Iwashima, Y., Katsuya, T., Ishikawa, K., Ouchi, N. et al., Hypoadiponectinemia is an independent risk factor for hypertension. Hypertension 2004, 43, 1318-1323.
57. Ouchi, N., Kihara, S., Funahashi, T., Matsuzawa, Y., Walsh, K., Obesity, adiponectin and vascular inflammatory disease. Curr. Opin. Lipidol. 2003, 14, 561-566.
58. Haluzik, M., Haluzikova, D., The role of resistin in obesityinduced insulin resistance. Curr. Opin. Investig. 2006, 7, 306-311.
59. Steppan, C. M., Bailey, S. T., Bhat, S., Brown, E. J. et al., The hormone resistin links obesity to diabetes. Nature 2001, 409, 307-312.
60. Banerjee, R. R., Rangwala, S. M., Shapiro, J. S., Rich, A. S. et al., Regulation of fasted blood glucose by resistin. Science 2004, 303, 1195-1198.
61. Way, J. M., Gorgun, C. Z., Tong, Q., Uysal, K. T. et al., Adipose tissue resistin expression is severely suppressed in obesity and stimulated by peroxisome proliferator-activated receptor gamma agonists. J. Biol. Chem. 2001, 276, 25651-25653.
62. Milan, G., Granzotto, M., Scarda, A., Calcagno, A. et al., Resistin and adiponectin expression in visceral fat of obese rats: effect of weight loss. Obes. Res. 2002, 10, 1095-1103.
63. Norata, G. D., Ongari, M., Garlaschelli, K., Raselli, S. et al., Plasma resistin levels correlate with determinants of the metabolic syndrome. Eur. J. Endocrinol. 2007, 156, 279-284.
64. Hotamisligil, G. S., Shargill, N. S., Spiegelman, B. M., Adipose expression of tumor necrosis factor-alpha: direct role in obesity-linked insulin resistance. Science 1993 259, 87-91.
65. Hotamisligil, G. S., Arner, P., Caro, J. F., Atkinson, R. L., Spiegelman, B. M., Increased adipose tissue expression of tumor necrosis factor-alpha in human obesity and insulin resistance. J. Clin. Invest. 1995, 95, 2409-2415.
66. Stephens, J. M., Pekala, P. H., Transcriptional repression of the C/EBP-alpha and GLUT4 genes in 3T3-L1 adipocytes by tumor necrosis factor-alpha. Regulations is coordinate and independent of protein synthesis. J. Biol. Chem. 1992, 267, 13580-13584.
67. Rui, L., Aguirre, V., Kim, J. K., Shulman, G. I. et al., Insulin/ IGF-1 and TNF-alpha stimulate phosphorylation of IRS-1 at inhibitory Ser307 via distinct pathways. J. Clin. Invest. 2001, 107, 181-189.
68. Paquot, N., Castillo, M. J., Lefebvre, P. J., Scheen, A. J., No increased insulin sensitivity after a single intravenous administration of a recombinant human tumor necrosis factor receptor: Fc fusion protein in obese insulin-resistant patients. J. Clin. Endocrinol. Metab. 2000, 85, 1316-1319.
69. Mohamed-Ali, V., Goodrick, S., Rawesh, A., Katz, D. R. et al., Subcutaneous adipose tissue releases interleukin-6, but not tumor necrosis factor-alpha, in vivo. J. Clin. Endocrinol. Metab. 1997, 82, 4196-4200.
70. Fried, S. K., Bunkin, D. A., Greenberg, A. S., Omental and subcutaneous adipose tissues of obese subjects release interleukin-6: depot difference and regulation by glucocorticoid. J. Clin. Endocrinol. Metab. 1998, 83, 847-850.
71. Straub, R. H., Hense, H. W., Andus, T., Scholmerich, J. et al., Hormone replacement therapy and interrelation between serum interleukin-6 and body mass index in postmenopausal women: a population-based study. J. Clin. Endocrinol. Metab. 2000, 85, 1340-1344.
72. Muller, S., Martin, S., Koenig, W., Hanifi-Moghaddam, P. et al., Impaired glucose tolerance is associated with increased serum concentrations of interleukin 6 and co-regulated acute-phase proteins but not TNF-alpha or its receptors. Diabetologia 2002, 45, 805-812.
73. Kado, S., Nagase, T., Nagata, N., Circulating levels of interleukin-6, its soluble receptor and interleukin-6/interleukin-6 receptor complexes in patients with type 2 diabetes mellitus. Acta. Diabetol. 1999, 36, 67-72.
74. Fasshauer, M., Kralisch, S., Klier, M., Lossner, U. et al., Adiponectin gene expression and secretion is inhibited by interleukin-6 in 3T3-L1 adipocytes. Biochem. Biophys. Res. Commun. 2003, 301, 1045-1050.
75. Yoon, H. J., Moon, M. E., Park, H. S., Im, S. Y., Kim, Y. H., Chitosan oligosaccharide (COS) inhibits LPS-induced inflammatory effects in RAW 264.7 macrophage cells. Biochem. Biophys. Res. Commun. 2007, 358, 954-959.
76. Kim, H. M., Hong, S. H., Yoo, S. J., Baek, K. S. et al., Differential effects of chitooligosaccharides on serum cytokine levels in aged subjects. J. Med. Food 2006, 9, 427-430.
77. Rosen, E. D., Walkey, C. J., Puigserver, P., Spiegelman, B. M., Transcriptional regulation of adipogenesis. Genes Dev. 2000, 14, 1293-1307.
78. Juvet, L. K., Andresen, S. M., Schuster, G. U., Dalen, K. T. et al., On the role of liver X receptors in lipid accumulation in adipocytes. Mol. Endocrinol. 2003, 17, 172-182.
79. Seo, J. B., Moon, H. M., Kim, W. S., Lee, Y. S. et al., Activated liver X receptors stimulate adipocyte differentiation through induction of peroxisome proliferator-activated receptor gamma expression. Mol. Cell. Biol. 2004, 24, 3430-3444.
80. Ntambi, J. M., Kim, Y. C., Adipocyte differentiation and gene expression. J. Nutr. 2000, 130, 3122-3126.
81. Hwang, C. S., Loftus, T. M., Mandrup, S., Lane, M. D., Adipocyte differentiation and leptin expression. Annu. Rev. Cell. Dev. Biol. 1997, 13, 231-259.
82. MacDougald, O. A., Lane, M. D., Transcriptional regulation of gene expression during adipocyte differentiation. Annu. Rev. Biochem. 1995, 64, 345-373.
83. Darlington, G. J., Ross, S. E., MacDougald, O. A., The role of C/EBP genes in adipocyte differentiation. J. Biol. Chem. 1998, 273, 30057-30060.
84. Kim, J. B., Spiegelman, B. M., ADD1/SREBP1 promotes adipocyte differentiation and gene expression linked to fatty acid metabolism. Genes Dev. 1996, 10, 1096-1107.
85. Tontonoz, P., Kim, J. B., Graves, R. A., Spiegelman, B. M., ADD1: a novel helix-loop-helix transcription factor associated with adipocyte determination and differentiation. Mol. Cell. Biol. 1993, 13, 4753-4759.
86. Tabor, D. E., Kim, J. B., Spiegelman, B. M., Edwards, P. A., Identification of conserved cis-elements and transcription factors required for sterol-regulated transcription of stearoyl-CoA desaturase 1 and 2. J. Biol. Chem. 1999, 274, 20603-20610.
87. Hsu, C. L., Yen, G. C., Effects of flavonoids and phenolic acids on the inhibition of adipogenesis in 3T3-L1 adipocytes. J. Agric. Food. Chem. 2007, 55, 8404-8410.
88. Yang, J. Y., Della-Fera, M. A., Rayalam, S., Ambati, S. et al., Enhanced inhibition of adipogenesis and induction of apoptosis in 3T3-L1 adipocytes with combinations of resveratrol and quercetin. Life Sci. 2008, 82, 1032-1039.